CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Alia Therapeutics
Company Type: Therapeutic development
Main focus: Developing CRISPR-based therapies to treat genetic diseases
Company stage: Pre-clinical
Diseases: Autosomal-dominant retinitis pigmentosa and other genetic diseases.
Genome-editing tool: CRISPR-Cas
Funding stage: Seed
Location: Trento, Trentino-Alto Adige, Italy
Website: www.aliatherapeutics.com/en/home/
Pipeline: www.aliatherapeutics.com/en/technology/
Partners:
Alia Therapeutics is a biotechnology company focused on developing CRISPR-based therapies to treat genetic diseases. Alia's research is centered on optimising gene-editing tools to improve safety, precision, and efficiency in therapeutic applications, with the goal of providing targeted treatments for a range of inherited disorders. The company’s first pipeline programme aims to develop a gene-editing treatment for autosomal-dominant retinitis pigmentosa.
